TufiaChristineHaddadMD

Oncology • Rochester, MN

Breast Cancer, Clinical Informatics

Professor, Oncology, Mayo Clinic School of Graduate Medical Education

Join to view full profile

Dr. Haddad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Haddad's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 2004 - 2007
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2001 - 2004
Creighton University School of MedicineClass of 2001
Marquette UniversityB.S., Biology, Magna Cum Laude, 1991 - 1995

Certifications & Licensure

MN State Medical License 2002 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

HIMSS Future50 Clinical Leader Health Information and Management Systems Society, 2021
Best Teacher- New Faculty, by the Mayo Clinic Internal Medicine Residency Program 2013
Department of Medicine Educational Excellence Award 2008
Senior Medical Resident Teaching Award 2004
ACE Award for Resident Excellence 2003
Alpha Omega Alpha, Medical Honor Society 2000
Nominee, Aesculapian Student Humanitarian Award, Peer Selected Recipient 1999
Aesculapian Student Humanitarian Award, Peer Selected Recipient 1998
Phi Beta Kappa-National Honor Society
Join now to see all

Clinical Trials

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer Start of enrollment: 2008 Jul 30
Completed
Phase 2
Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2014 Dec 05
Completed
Phase 1
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer Start of enrollment: 2017 Jul 06
Active, not recruiting
Phase 2
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer Start of enrollment: 2017 Aug 03
Active, not recruiting
Phase 2
Effectiveness of Nurse-based Care Coordination on Readmissions Among Primary Care Patients: a Stepped Wedge Cluster Randomized Trial Start of enrollment: 2020 Jan 01
Completed
Not Applicable
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer Start of enrollment: 2020 Apr 28
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

8 citations
Avoiding the Faux Equalizer
Joshua C. Pritchett, Tufia C. Haddad
Mayo Clinic Proceedings. 2021-10-30
24 citations
Characterizing axillary web syndrome: ultrasonographic efficacy.
Linda A Koehler, David W. Hunter, Tufia C. Haddad, Anne H. Blaes, Alan T. Hirsch
Lymphology. 2014-12-01
34 citations
Movement, Function, Pain, and Postoperative Edema in Axillary Web Syndrome
Linda A Koehler, Anne H. Blaes, Tuffia C. Haddad, David W. Hunter, Alan T. Hirsch
Physical Therapy. 2015-10-01

Journal Articles

Smoking and quality of life among survivors of breast, colorectal and endometrial cancers in a prospective cohort study
Jang S, Prizment A, Haddad T, Robien K, Lazovich D, J Cancer Surviv, 1/1/2011
Nonpharmacologic Complementary Therapies for Symptom Management in Breast Cancer Survivors
Blaes A, Kreitzer MJ, Torkelson C, Haddad T, Semin Oncol, 1/1/2011
Conflict of interest in economic analysis of aromatase inhibitors in breast cancer: a systematic review
Jang S, Chae YK, Haddad T, and Majhail N, Breast Cancer Res Treat, 1/1/2010
Pregnancy and Thrombophilia
Patnaik M, Haddad T, Morton C, Expert Review of Cardiovascular Therapy, 1/1/2007
Can genes predict the future?
Haddad T and D Yee, Minnesota Physician, 1/1/2007
Targeting the Insulin-like Growth Factor Axis as Cancer Therapy
Haddad T and Yee D, Future Oncology, 1/1/2006
Chemotherapy-induced thrombosis
Haddad TC and EW Greeno, Thrombosis Research, 1/1/2006
Characterization and partial purification of the IGF-dependent IGF Binding Protein-4-specific protease from human fibroblast conditioned media
Lawrence JB, Bale LK, Haddad TC, Clarkson JT, Conover CA, Growth Hormone & IGF Research, 1/1/1999
Evaluation of Continuous Infusion Suramin in Metastatic Breast Cancer: Impact on Plasma Levels of Insulin-like Growth Factors (IGF) and IGF-binding Proteins
Lawrence JB, Conover CA, Haddad TC, Ingle JN, Reid JM, Ames MM, Suman VJ, Marks RS, Erlichman C, and Hartmann LC, Clin Cancer Res, 1/1/1997
Insulin and IL-4 Desensitization to the Mitogenic Effects of IGF-I
Haddad T and Conover C, Journal of Biochemistry, 1/1/1997
Join now to see all

Abstracts/Posters

New-Onset Heart Failure in Association with Severe Hypertension During Trastuzumab Therapy.
Herrmann J, Herrmann SM, and Haddad TC, Mayo Clin Proc, 1/1/2014

Lectures

Impact of a cognitive computing clinical trial matching system in an ambulatory oncology practice.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Mayo Clinic Experts Advance Chemo-Free, Low-Dose RadiationNovember 3rd, 2024
Prognostic Biomarker Identified in Triple-Negative Breast Cancer: Potential to Reduce Chemotherapy UseOctober 30th, 2024
Leading Scientists Share Advances in Omics-Based Clinical Trials at 12th Annual Individualizing Medicine ConferenceMay 3rd, 2023
Join now to see all